ArticleZeitschrift fur Gastroenterologie2026
Assessing the Relationship Between Steatotic Liver Disease and Barrett's Esophagus: A Cross-Sectional Analysis of 5507 Screening Participants.
Article in Zeitschrift fur Gastroenterologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Barrett's esophagus (BE) is the main precursor of esophageal adenocarcinoma (~2% prevalence in Western adults). Steatotic liver disease (SLD), affecting ~25% of adults, is linked to systemic inflammation, but its relationship with BE is unclear. Methods: In the population-based Salzburg Colon Cancer Prevention Initiative (2007-2020), we analyzed 5507 asymptomatic screening participants. SLD was diagnosed by ultrasound and classified as MASLD or MetALD; BE was confirmed endoscopically and histologically. Associations were assessed using multivariable logistic regression adjusting for demographic, metabolic, and clinical factors. Results: SLD was present in 2550 participants and clustered with diabetes and metabolic syndrome. BE was found in 62 individuals (1.0% without SLD, 1.5% with MASLD, 1.1% with MetALD; P = 0.28). After adjustment, MASLD (OR 1.28; 95% CI 0.74-2.21) and MetALD (OR 0.66; 95% CI 0.16-2.85) were not significantly associated with BE. Female sex was protective (OR 0.26; 95% CI 0.13-0.50), while hiatal hernia increased BE risk (OR 2.05; 95% CI 1.16-3.60). Conclusion: In this population-based cohort, MASLD and MetALD were not clearly associated with BE. Current data do not support incorporating SLD status into BE screening algorithms, although modest risk increases cannot be ruled out.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.